8:00 am Online Registration & Virtual Coffee Networking

Improving Future Gene Therapy Analytical Development Strategies

8:30 am Defining, Developing & Managing a Functionally Relevant Set of Assays for AAV Vectors


Discussing the challenges of AAV gene therapy analytical development

  • With no industry defined assay package, how best to decide which panel of assays are needed for release, stability, and characterization
  • Using platform approaches to achieve faster timelines
  • Exploring sampling plan strategies considering volume required

9:00 am Analytical Comparability Requirements During the Development & Commercialisation of Gene Therapy Products

  • Clare Blue Director of Analytical Development, Biogen


  • What is analytical comparability?
  • Requirement for analytical comparability during and post clinical development
  • Regulatory expectations
  • Defining comparability acceptance criteria
  • Bridging studies and assay performance monitoring to ensure comparability


9:30 am Session Reserved for Bio-Rad

10:00 am Panel Discussion: Addressing the Current Challenges of Analytical Development Between Phases


Hear from gene therapy developers at different stages of the development timeline, from manufacturing to commercialization. Topics to discuss include:

  • Encouraging the use of novel technologies and breaking free from traditional approaches
  • Maximising the use of limited materials
  • Overcoming the standardization issue and lack of reference material
  • Comparability: what improvements can be made?
  • Brexit: What are the consequences for gene therapy developers?

10:30 am Virtual Speed Networking


Specifically designed to connect you with new contacts from the most active companies in the field, the, now virtual, renowned Speed Networking session will be one of the most valuable hours you will spend at Gene Therapy Analytical Development Europe.

10:50 am Break: Morning Refreshments, Exhibition & Private Chat Time


Grab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with your sponsors, discover their technologies and set up private conversations with fellow attendees to form connections for future partnerships.

Improving Potency Assay Development to Demonstrate Clinical Relevance

11:10 am Case Study: Developing a Functional Potency Assay to Demonstrate a Link to Effectiveness

  • Elina Hessels Senior Scientist, Lead Assay Development, UniQure


  • Background potency testing
  • Approaches to be used for potency testing
  • Case study on a potency test development for a Phase I/II product

11:40 am AAV Titration ELISAs: a Robust & Reliable Tool for AAV Quantification


• Comparison between PROGEN’s ELISA and other analytical methods
• Technical parameters of PROGEN´s Titration ELISA
• Procedure of ELISA calibration

12:10 pm Phase-Appropriate Analytical Control Strategies for Recombinant AAV-Based Gene Therapy Products: Case Studies in the Characterization of a Process-Related Impurity and Development of an In-Vitro Potency Assay

  • Eric Yearley Principal Scientist, Analytical Development, BridgeBio


  • Overall analytical control strategy: CQAs assessment and corresponding assays, stability program and benefits of implementing a CRO for phase I analytical development
  • Example of an in-house in vitro potency assay to measure protein expression
  • Current development of an enzymatic in vitro potency assay
  • Development of an assay to measure residual detergent for in process and DS/DP samples

1:00 pm Lunch & Analytical Technologies Roundtable Discussion

  • Ian Anderson Senior Manager, Analytical Sciences, Allergan
  • David Dobnik Scientific Associate, Head of Laboratory for Therapeutic Viruses, National Institute of Biology
  • Doyoung Lee Senior Scientist, Lead UK DRI Vector Core, King’s College London

Exploring the Use of Next Generation Sequencing for Different Applications

2:00 pm Accurate & Sensitive Identification of Nucleic Acid Impurities in AAV Vector Samples by High-Throughput Sequencing

  • David Dobnik Scientific Associate, Head of Laboratory for Therapeutic Viruses, National Institute of Biology


  • Using HTS to identify all nucleic acid impurities present in AAV vectors
  • Highlighting differences between short and long read platforms
  • Case study on AAV vectors, focusing on encapsidated impurities
  • Discussing the limitations of this method and its regulatory implications

2:30 pm Process & Product Impurities


Talk details to be confirmed.

3:15 pm Afternoon Refreshments & Networking

Assessing Analytical Methods for Gene Therapy Characterisation

3:45 pm Digital PCR – State of the Art Vector Genome Titering Or Even More?


  • Digital PCR: The Basic Principles
  • Reducing variation: why is digital PCR considered better than qPCR?
  • Potential drawbacks of this innovative technique
  • Strategies of designing the transgene target sequences and the individual influence on the obtained results

4:15 pm AAV Manufacturing In-Process Control


• New column to better separate empty and full AAV particles will be introduced
• Rapid and sensitive analytics for in-process control of AAV manufacturing using HPLC and different in-line detectors will be shown
• New ultra-sensitive DNA assay showing major AAV-associated DNA contamination will be presented

4:45 pm Mass Spectrophotometry Based Analytical Methods for AAV Protein Characterisation & Residual Protein Determination

  • Uditha deAlwis Executive Director Analytical Sciences (AD/QC), Sarepta Therapeutics


  • AAV protein identity and post translational modification determination in a denaturant free system
  • A method that utilizes the natural denaturation temperature of AAV to achieve capsid protein recovery and high-resolution mass analysis
  • Host cell and media component quantification at low ng/mL levels. The presence of host cell protein debris and the determination of these components has been conducted by ELISA methods
  • A novel method of identifying all proteins that may be contaminating an AAV preparation and then quantifying the contaminates will be discussed

5:15 pm Assessing Analytical Tools for the Characterisation of Empty, Partial & Full AAV Particles

  • Ian Anderson Senior Manager, Analytical Sciences, Allergan


  • Analytical Ultracentrifugation (AUC): What value does AUC provide if not suitable for GMP environment?
  • Discussing the limitations such as low sensitivity and requiring a lot of material
  • Determining the high-resolution value and benefit of using HPLC

5:45 pm End of Day & Virtual Happy Hour


Grab a drink and visit the exhibitions available, set up private conversations with your fellow online attendees and network from the comfort of your own home.